# SARS-CoV-2 Spike glycoprotein [mRNA]

## Pfizer-BioNTech (5-11y/o) 0.2mL/dose (1.3mL/vial)

| TAH Drug Code      | [IBNT1](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IBNT1)                                                                       |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | The Pfizer-BioNTech COVID-19 Vaccine Standing Orders for Administering Vaccine to Persons 5 through 11 Years of Age                          |
| Dosing             | IM, 0.2 mL, 5-11 years old, 2-dose series separated by at least 3 weeks                                                                      |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                |
| Contraindications  | Hypersensitivity to the active substance or to any of the excipients.                                                                        |
| Adverse Effects    | erythema at injection site, pain at injection site, and swelling at injection site. asthenia, fatigue, fever, headache, myalgia, and nausea. |
| Pregnancy          | Unknown                                                                                                                                      |
| Lactation          | Unknown                                                                                                                                      |
| More Info          | [UpToDate](https://www.uptodate.com/contents/sars-cov-2-spike-glycoprotein-[mrna]-drug-information)                                          |

## Pfizer-BioNTech (6M-4歲) 0.2mL/dose (0.4mL/vial)

| TAH Drug Code      | [IBNT6M](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IBNT6M)                                                                                                                                                                                                                     |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | The Pfizer-BioNTech COVID-19 Vaccine Standing Orders for Administering Vaccine to Persons 6 months to 4 Years of Age                                                                                                                                                                         |
| Dosing             | 6 months to 4 years: Primary series, 0.2 mL IM for 2 doses, administered 3 weeks apart, followed by a third dose (0.2 mL) administered at least 8 weeks after the second dose.                                                                                                               |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                |
| Contraindications  | Hypersensitivity to the active substance or to any of the excipients.                                                                                                                                                                                                                        |
| Adverse Effects    | Common Dermatologic: Erythema at injection site, Injection site pain, Swelling at injection site. Musculoskeletal: Arthralgia, Myalgia. Neurologic: Headache. Other: Fatigue, Fever, Shivering. Serious Gastrointestinal: Appendicitis. Immunologic: Anaphylaxis, Hypersensitivity reaction. |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                      |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                      |
| More Info          | [UpToDate](https://www.uptodate.com/contents/sars-cov-2-spike-glycoprotein-[mrna]-drug-information)                                                                                                                                                                                          |

## BA1雙價Moderna(Covid19) 0.5mL/dose(2.5mL/vial)

| TAH Drug Code      | [ICOMDBA1](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ICOMDBA1)                                                                                                                                                   |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Moderna COVID-19 Vaccine, for active immunization to prevent COVID-19 in individuals 18 years of age and older.                                                                                                                |
| Dosing             | IM, 0.5 mL, > or = 18 years, As booster vaccination. At least 3 months after the second or last booster dose. As a Covid-19 vaccine, bivalent Original/Omicron BA.1 which contains elasomeran and an additional mRNA molecule. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                  |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                  |
| Contraindications  | Do not administer the Moderna COVID-19 Vaccine to individuals with a known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Moderna COVID-19 Vaccine.                                         |
| Adverse Effects    | erythema at injection site, pain at injection site, and swelling at injection site. asthenia, fatigue, fever, headache, myalgia, and nausea.                                                                                   |
| Pregnancy          | Unknown                                                                                                                                                                                                                        |
| Lactation          | Unknown                                                                                                                                                                                                                        |
| More Info          | [UpToDate](https://www.uptodate.com/contents/sars-cov-2-spike-glycoprotein-[mrna]-drug-information)                                                                                                                            |

## BA4/5次世代Moderna(Covid19) 0.5mL/dose(2.5mL/vial)

| TAH Drug Code      | [ICOMDBA5](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ICOMDBA5)                                                                                                                                                                                                                                                                                                                                                                                  |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Moderna COVID-19 Vaccine, for active immunization to prevent COVID-19 in individuals 18 years of age and older.                                                                                                                                                                                                                                                                                                                                               |
| Dosing             | IM, 0.5 mL, > or = 12 years, As booster vaccination. At least 3 months after the second or last booster dose. As a Covid-19 vaccine, bivalent Original/Omicron BA.4/5 which contains elasomeran and an additional mRNA molecule. IM, 0.25 mL, 6-11 years, As booster vaccination. At least 3 months after the second or last booster dose. As a Covid-19 vaccine, bivalent Original/Omicron BA.4/5 which contains elasomeran and an additional mRNA molecule. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Contraindications  | History of a severe allergic reaction (e.g., anaphylaxis) to any component of the Moderna COVID-19 Vaccine.                                                                                                                                                                                                                                                                                                                                                   |
| Adverse Effects    | erythema at injection site, pain at injection site, and swelling at injection site. asthenia, fatigue, fever, headache, myalgia, and nausea.                                                                                                                                                                                                                                                                                                                  |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| More Info          | [UpToDate](https://www.uptodate.com/contents/sars-cov-2-spike-glycoprotein-[mrna]-drug-information)                                                                                                                                                                                                                                                                                                                                                           |

## COVID-19 Vaccine BioNTech 0.3mL/dose (0.45mL/vial)

| TAH Drug Code      | [ICOVBNT](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ICOVBNT)                                                                   |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | BioNTech COVID-19 Vaccine, for active immunization to prevent COVID-19 in individuals 12 years of age and older.                             |
| Dosing             | IM, 0.3 mL, > or = 18 years 2 doses administered 3 weeks apart. (Taiwan CDC suggests 2 doses administered 4 weeks apart.)                    |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                |
| Contraindications  | Hypersensitivity to the active substance or to any of the excipients.                                                                        |
| Adverse Effects    | erythema at injection site, pain at injection site, and swelling at injection site. asthenia, fatigue, fever, headache, myalgia, and nausea. |
| Pregnancy          | Unknown                                                                                                                                      |
| Lactation          | Unknown                                                                                                                                      |
| More Info          | [UpToDate](https://www.uptodate.com/contents/sars-cov-2-spike-glycoprotein-[mrna]-drug-information)                                          |

## COVID-19 Vaccine Moderna 0.5mL/dose (5mL/vial)

| TAH Drug Code      | [ICOVMDN](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ICOVMDN)                                                                                                             |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Moderna COVID-19 Vaccine, for active immunization to prevent COVID-19 in individuals 18 years of age and older.                                                                        |
| Dosing             | IM, 0.5 mL, > or = 18 years 2 doses administered 28 days apart.                                                                                                                        |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                          |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                          |
| Contraindications  | Do not administer the Moderna COVID-19 Vaccine to individuals with a known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Moderna COVID-19 Vaccine. |
| Adverse Effects    | erythema at injection site, pain at injection site, and swelling at injection site. asthenia, fatigue, fever, headache, myalgia, and nausea.                                           |
| Pregnancy          | Unknown                                                                                                                                                                                |
| Lactation          | Unknown                                                                                                                                                                                |
| More Info          | [UpToDate](https://www.uptodate.com/contents/sars-cov-2-spike-glycoprotein-[mrna]-drug-information)                                                                                    |

## COVID-19 XBB.1.5 0.5mL/dose (2.5mL/vial)

| TAH Drug Code      | [ICOXBB15](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ICOXBB15)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | For active immunization in children aged 6 months and above, adolescents, and adults to prevent COVID-19 (severe acute respiratory syndrome coronavirus 2 disease).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Dosing             | For children aged 6 months to 4 years: (1) No prior COVID-19 vaccination and no known SARS-CoV-2 infection history: Two doses, 0.25 mL (25 micrograms) each, at least 28 days apart. (2) Previously received one dose of any Spikevax vaccine: Single 0.25 mL (25 micrograms) dose, at least 28 days after the previous dose. (3) Previously received two doses of Spikevax or had a SARS-CoV-2 infection: Single 0.25 mL (25 micrograms) dose, at least 3 months after the previous dose. For children aged 5 to 11 years: Single 0.25 mL (25 micrograms) dose, with a minimum 3-month interval if previously vaccinated. For adolescents aged 12 and adults: Single 0.5 mL (50 micrograms) dose, with a minimum 3-month interval if previously vaccinated.                                                                                                                                                                                                                                                                                         |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Contraindications  | Known history of severe allergic reactions (eg, anaphylaxis) to any component of the Moderna COVID-19 vaccine (inactive ingredients include tromethamine, acetic acid, sodium acetate, sucrose, sphingomyelin, cholesterol, distearoylphosphatidylcholine, and polyethylene glycol [ie, PEG2000-DMG]) or severe allergic reaction following a previous dose of a Moderna COVID-19 vaccine.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Adverse Effects    | Common: Erythema at injection site (Adult, 2.4-9%; adolescent, 13.5-19.5%; pediatric, 3.5-18.7%), Injection site pain (Adult, 73.9-89.9%; adolescent, 92.4-93.1%; pediatric, 37.4-94.8%), Swelling at injection site (Adult, 4.5-12.7%; adolescent, 16.2-20.5%; pediatric, 2.8-17%), Nausea and vomiting (Adult, 5.2-21.4%; adolescent, 11.3-23.9%; pediatric, 6.8-24%), Axillary lymphadenopathy, Tenderness (Adult, 6.1-16.2%; adolescent, 21-23.3%; pediatric, 15.5-18%), Arthralgia (Adult, 16.4-45.6%; adolescent, 15-28.9%; pediatric, 6.2-16.1%), Myalgia (Adults, 19.7-61.7%; adolescents, 26.9-46.6%; pediatrics, 9.9-28.2%), Headache (Adult, 24.5-63%; adolescent, 43.4-70.2%; pediatric, 11.5-54.3%), Fatigue (Adult, 33.3-67.8%; adolescent, 47.9-67.8%; pediatric, 40.1-64.5%), Fever (Adult, 0.3-17.4%; adolescent, 2.5-12.2%; pediatric, 3.3-23.9%), Shivering (Adult, 5.3-48.7%; adolescent, 18.4-43%; pediatric, 6.4-30.3%) Serious: Myocarditis, Pericarditis, Facial swelling, Anaphylaxis, Hypersensitivity reaction (1.5-4.3%) |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| More Info          | [UpToDate](https://www.uptodate.com/contents/sars-cov-2-spike-glycoprotein-[mrna]-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

